Usana Health Sciences INC 10-Q quarterly reports

USANA Health Sciences reported a net loss of $21.4 million for the second quarter of 2026, impacted by a $29.1 million goodwill impairment charge for its Hiya segment and declining sales in its Core Nutritional business.

USANA Health Sciences reported a 0.3% increase in net sales to $250.2 million for Q1 2026, but net earnings attributable to USANA decreased by 20.1% to $7.5 million, impacted by lower operating margins and a higher tax rate.

USANA Health Sciences reported a net loss of $6.5 million in Q3 2025, primarily due to a significantly higher effective tax rate and a decline in its core direct selling segment, despite revenue growth from the Hiya acquisition.

USANA Health Sciences reports a 7.4% drop in Q2 net earnings and a 3.7% decrease in diluted EPS, despite a 10.8% revenue increase driven by the Hiya acquisition.

USANA Health Sciences' Q1 2025 results show a net sales increase driven by the Hiya acquisition, but a decrease in net earnings due to amortization costs and currency headwinds.

USANA Health Sciences experienced a decrease in both sales and earnings for the third quarter of 2024, primarily due to a challenging economic environment impacting customer acquisition and spending.

USANA Health Sciences experienced a decrease in both sales and earnings for the second quarter of 2024, primarily due to a decline in active customers and average customer spend.

USANA Health Sciences reported a decrease in net sales and earnings for the first quarter of 2024, primarily due to lower customer spending and unfavorable currency exchange rates.